Ibogaine; authorize MSDH to select a consortium to conduct a drug development clinical trial to secure FDA's approval of.

This bill would authorize Mississippi's State Department of Health to select a consortium (composed of a drug developer, university, and hospital) to conduct clinical trials using ibogaine. The goal is to seek U.S. Food and Drug Administration (FDA) approval for ibogaine as a treatment for opioid use disorder, co-occurring substance use disorders, and other neurological or mental health conditions. The consortium must submit a detailed proposal outlining trial design, FDA coordination, and securing non-state matching funds before receiving state funding. If approved by the FDA, the bill requires ibogaine treatment to be administered under physician supervision in a hospital or licensed healthcare facility.